Skip to main content

An Open Label Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently receiving Treatment on Ublituximab and/or TGR-1202 Trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

TG Therapeutics, Inc

Start Date

February 20, 2018

End Date

February 14, 2023
 

Administered By

Duke Cancer Institute

Awarded By

TG Therapeutics, Inc

Start Date

February 20, 2018

End Date

February 14, 2023